Compare AMTB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | GERN |
|---|---|---|
| Founded | 1979 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 1.1B |
| IPO Year | 2018 | N/A |
| Metric | AMTB | GERN |
|---|---|---|
| Price | $22.93 | $1.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $23.67 | $2.17 |
| AVG Volume (30 Days) | 225.9K | ★ 15.1M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.29 | $26.91 |
| Revenue Next Year | $7.67 | $43.75 |
| P/E Ratio | $52.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.62 | $1.04 |
| 52 Week High | $24.38 | $2.01 |
| Indicator | AMTB | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 40.05 |
| Support Level | $21.98 | $1.24 |
| Resistance Level | $24.02 | $1.49 |
| Average True Range (ATR) | 0.65 | 0.09 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 43.84 | 10.14 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.